Glaukos (GKOS) Stock Price, News & Analysis

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1-year price targets for Glaukos' shares. Their GKOS share price targets range from $65.00 to $120.00. On average, they anticipate the company's share price to reach $99.80 in the next year. This suggests a possible upside of 3.1% from the stock's current price.
View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $79.49 at the beginning of 2024. Since then, GKOS stock has increased by 21.8% and is now trading at $96.8050.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GKOS earnings forecast.

Glaukos will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Glaukos Co. (NYSE:GKOS) released its quarterly earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.07. The medical instruments supplier earned $82.40 million during the quarter, compared to the consensus estimate of $81 million. Glaukos had a negative net margin of 42.79% and a negative trailing twelve-month return on equity of 22.67%. The firm's revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.53) earnings per share.

ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Momentum ETF (XSMO), Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC).

Glaukos updated its FY 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million.

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.